Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06355219
Status:
COMPLETED
Last Update Posted:
2024-05-21
First Post:
2024-03-29
Brief Title:
Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines
Sponsor:
Ali Aminian
Organization:
The Cleveland Clinic
Study Overview
Official Title:
Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes and Obesity Comparison of Metabolic Surgery Versus GLP-1 Receptor Agonists
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
M6
Brief Summary:
The goal of this study is to compare the impact of metabolic surgery and a class of anti-diabetes medications Glucagon-like peptide-1 receptor agonistsGLP-1 RAs on occurrence of diseases involving small and large vessels such as heart disease kidney disease and disease of the retina a part of the eye as well as deaths
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None